<DOC>
	<DOC>NCT00171184</DOC>
	<brief_summary>The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged &gt;Ý 65 years with OAB.</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged &gt; 65 Years With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Symptoms of OAB for at least six months prior to Visit 3 Symptoms of OAB during the 7 day diary period immediately preceding Visit 3: ≥ 1 UUIE on average per day and ≥ 10 episodes of micturition on average per day A total daily urinary volume &gt; 3000 ml or a mean volume voided per micturition of &gt; 300 ml as verified in the micturition diary before randomization Postvoid residual (PVR) urinary volume &gt; 100 ml Clinically significant stress urinary incontinence as determined by the investigator Clinically significant bladder outlet obstruction as determined by the investigator Concomitant diseases in which the use of anticholinergic drugs is contraindicated, e.g. urinary retention, gastric retention, uncontrolled narrowangle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh B and C), severe ulcerative colitis, toxic megacolon. Other protocol inclusion / exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Overactive bladder, Darifenacin, M3 muscarinic receptor antagonist, elderly population</keyword>
</DOC>